Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers after renal transplantation
Research output: Contribution to journal › Review article › Contributed › peer-review
Contributors
Abstract
Renin-angiotensin system blockade retards the progression of diabetic and non-diabetic chronic kidney disease of the native kidneys. Though most patients suffer from a significant renal insufficiency (chronic kidney disease stage III) and a concomitant heart disease after renal transplantation, there is up to now no evidence supporting the use of inhibitors of the renin-angiotensin system in these patients. We wish to summarize the available evidence on the use of inhibitors of the renin-angiotensin system after renal transplantation. We specifically discuss potential beneficial as well as adverse effects of a renin-angiotensin system blockade. In addition, we review their influence on morphologic and biochemical markers as well as on renal function, graft and patient survival after renal transplantation.
Details
Original language | English |
---|---|
Pages (from-to) | 33-36 |
Number of pages | 4 |
Journal | Clinical Transplantation |
Volume | 23 |
Issue number | Suppl 21 |
Publication status | Published - Dec 2009 |
Peer-reviewed | Yes |
Externally published | Yes |
External IDs
PubMed | 19930314 |
---|
Keywords
Sustainable Development Goals
ASJC Scopus subject areas
Keywords
- Angiotensin-converting enzyme inhibitor, Angiotension II type 1 receptor blocker, Chronic allograft dysfunction, Renal transplantation